
Opinion|Videos|June 21, 2024
AUA 2024: Outlining BOND-003 Data for NMIBC Therapy
Author(s)Gary Steinberg, MD, FACS
Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5



















